Oragenics (NYSE:OGEN) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN – Get Rating) in a report released on Tuesday. The firm set a “hold” rating on the stock.

Oragenics Price Performance

NYSE:OGEN opened at $7.17 on Tuesday. Oragenics has a 1-year low of $6.04 and a 1-year high of $27.29. The company has a 50-day moving average of $0.30 and a 200 day moving average of $0.30. The firm has a market cap of $841.08 million, a PE ratio of -55.15 and a beta of 0.37.

Oragenics Company Profile

(Get Rating)

Oragenics, Inc develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.